Login to Your Account



Abraxane Shows 'MPACT' on Survival in Pancreatic Cancer

By Catherine Shaffer
Staff Writer

Thursday, January 24, 2013
Celgene International Sarl, of Boudry, Switzerland, struck a blow against a notoriously difficult disease with positive overall survival results in a trial of Abraxane (nab-paclitaxel) in metastatic pancreatic cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription